Clinical Trials · NCT00112021

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Name: A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Pramlintide

Phase: Phase 2
Recruitment status: Completed
Sponsor: AstraZeneca
Enrollment: 400
Start date: May 2005
Locations: 21 sites, United States
Primary endpoint: To examine the effect of pramlintide on body weight in obese subjects

View Pramlintide compound reference